-
2022-501180-40-00
5
2022-06-17
Ewing Sarcoma
-
2023-503267-42-00
5
2022-06-10
Patients with a histological diagnosis of mismatch- repair deficient h
-
2023-506891-28-00
5
2022-05-02
The target population of interest in this study is participants with l
-
2023-509045-13-00
5
2022-02-28
Moderately to severely active Crohn's disease (CD)
-
2024-516336-97-00
4
2022-02-21
METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
-
2024-510578-25-00
5
2021-11-05
Histologically proven high-risk medulloblastoma, with any of the curre
-
2024-516728-32-00
10
2021-10-29
Indolent Systemic Mastocytosis and SSM
-
2024-513854-31-00
10
2021-10-27
Generalized Myasthenia Gravis
-
2024-510783-23-00
7
2020-10-29
Fallopian Tube Cancer
-
2024-510579-40-00
9
2020-10-07
Rhabdoyosarcoma
-
2023-507885-21-00
4
2020-08-18
Chronic Inflammatory Demyelinating Polyneuropathy
-
2022-501050-11-01
10
2020-07-13
Acute Lymphoblastic Leukaemia
-
2024-515625-29-00
5
2020-06-16
Apnea of prematurity
-
2022-501454-11-00
5
2020-02-05
standard risk ALK-positive anaplastic large cell lymphoma (ALCL)
-
2023-508926-91-00
5
2019-12-05
Stage IV childhood renal tumour with pulmonary +/- non-pulmonary
metas
-
2023-508689-14-00
5
2019-09-16
Sickle cell disease
-
2023-508101-24-00
5
2019-08-01
Lymphoblastic lymphoma
-
2023-504201-36-00
10
2018-12-21
Defined by parent protocol. The study will enroll all adult and paedia
-
2024-517019-57-00
6
2018-04-10
gastro-esophageal reflux disease
-
2024-516317-21-00
6
2018-04-09
gastro-esophageal reflux disease
-
2024-516110-38-00
5
2018-03-06
Hepatoblastoma and Hepatocellular Carcinoma
-
2024-512222-28-00
10
2015-06-02
Newly diagnosed with an intracranial or spinal ependymoma (all WHO gra
-
2026-525176-26-00
3
2026-05-28
Influenza
-
2025-522105-38-00
5
2026-02-02
Chronic Hepatitis Delta Infection